bosentan anhydrous has been researched along with Heart Failure, Systolic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernazzali, S; Caputo, M; Jelic, S; Maccherini, M; Mondillo, S; Padeletti, M; Tsioulpas, C; Zacà, V | 1 |
| Caspi, A; Cotter, G; Kaluski, E; Kobrin, I; Krakover, R; Leitman, M; Milo-Cotter, O; Moriconi, T; Rainisio, M; Reizin, L; Vered, Z; Zimlichman, R | 1 |
2 trial(s) available for bosentan anhydrous and Heart Failure, Systolic
| Article | Year |
|---|---|
Effect of bosentan on pulmonary hypertension secondary to systolic heart failure.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Echocardiography; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Heart Failure, Systolic; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Treatment Outcome; Vascular Resistance | 2013 |
Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study.
Topics: Antihypertensive Agents; Bosentan; Double-Blind Method; Female; Heart Failure, Systolic; Humans; Hypertension, Pulmonary; Male; Severity of Illness Index; Sulfonamides; Treatment Outcome; Ultrasonography; Ventricular Dysfunction, Left | 2008 |